These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 23338726)

  • 1. PCSK9 Inhibitors: potential in cardiovascular therapeutics.
    Do RQ; Vogel RA; Schwartz GG
    Curr Cardiol Rep; 2013 Mar; 15(3):345. PubMed ID: 23338726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction.
    Henry CA; Lyon RA; Ling H
    Vasc Health Risk Manag; 2016; 12():163-9. PubMed ID: 27143910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
    Joseph L; Robinson JG
    Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PCSK9 Inhibitors: Are We on the Verge of a Breakthrough?
    Yang E
    Clin Pharmacol Ther; 2015 Dec; 98(6):590-601. PubMed ID: 26369501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential role of anti-PCSK9 monoclonal antibodies in the management of hypercholesterolemia.
    Lepor NE; Contreras L; Desai C; Kereiakes DJ
    Rev Cardiovasc Med; 2014; 15(4):290-307; quiz 308-9. PubMed ID: 25662924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.
    Shen L; Peng H; Xu D; Zhao S
    Pharmacol Res; 2013 Jul; 73():27-34. PubMed ID: 23578522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PCSK9 inhibition in patients with hypercholesterolemia.
    Desai NR; Sabatine MS
    Trends Cardiovasc Med; 2015 Oct; 25(7):567-74. PubMed ID: 25771732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy.
    Pradhan AD; Aday AW; Rose LM; Ridker PM
    Circulation; 2018 Jul; 138(2):141-149. PubMed ID: 29716940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of anti-PCSK9 antibodies: Results from recent trials.
    Gouni-Berthold I
    Atheroscler Suppl; 2017 Nov; 30():9-18. PubMed ID: 29096867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?
    Dragan S; Serban MC; Banach M
    J Cardiovasc Pharmacol Ther; 2015 Mar; 20(2):157-68. PubMed ID: 24938457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PCSK9: From discovery to therapeutic applications.
    Farnier M
    Arch Cardiovasc Dis; 2014 Jan; 107(1):58-66. PubMed ID: 24373748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
    Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM
    Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of hypercholesterolemia for prevention of atherosclerotic cardiovascular disease: focus on the potential role of recombinant anti-PCSK9 monoclonal antibodies.
    Verma DR; Brinton EA
    Rev Cardiovasc Med; 2014; 15(2):86-101; quiz 101. PubMed ID: 25051126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy.
    Kohli P; Desai NR; Giugliano RP; Kim JB; Somaratne R; Huang F; Knusel B; McDonald S; Abrahamsen T; Wasserman SM; Scott R; Sabatine MS
    Clin Cardiol; 2012; 35(7):385-91. PubMed ID: 22714699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
    Toth PP; Worthy G; Gandra SR; Sattar N; Bray S; Cheng LI; Bridges I; Worth GM; Dent R; Forbes CA; Deshpande S; Ross J; Kleijnen J; Stroes ESG
    J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PCSK9 antibodies: A new class of lipid-lowering drugs.
    Gouni-Berthold I
    Atheroscler Suppl; 2015 May; 18():21-7. PubMed ID: 25936300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid lowering with PCSK9 inhibitors.
    Dadu RT; Ballantyne CM
    Nat Rev Cardiol; 2014 Oct; 11(10):563-75. PubMed ID: 24958078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics.
    Stein EA; Swergold GD
    Curr Atheroscler Rep; 2013 Mar; 15(3):310. PubMed ID: 23371064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.